A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- NA · SEQUENTIAL · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 260
- Population
- ALL · 12 Years to 120 Years
- Duration
- 2022-11-18 to 2028-06-25
- Intervention
- Melphalan; Sirolimus; Total Body Irradiation (TBI); Cyclophosphamide; Mycophenolate Mofeti; Fludarabine; Allogeneic HSCT; Mesna; Filgrastim
- Comparator
- Donors (Haplo HCT); Donors (Matched HCT)
- Outcomes measured
- Phase II: Evaluate the efficacy of PTCy, at the lowest dose determined for each HLA-matching arm from phase I, as asses…; Phase I: Determine the lowest effective dose of PTCy in combination with sirolimus and mycophenolate mofetil as GVHD pr…; Estimate rates of symptomatic BK virus cystitis. (Phase I and II) — 100 days; Estimate rates of hematopoietic recovery/engraftment. (Phase I and II) — day 28, 42, and 100; Estimate rates of Grade II-IV and III-IV acute GVHD at 100 days (Phase I and II) — 100 days; Estimate non-relapse mortality at one year (Phase II only) — 1 year; Estimate overall survival and progression-free survival at one year (Phase II only) — 1 year; Estimate incidence progression/relapse at one year (Phase II only) — 1 year; Describe and characterize cytokine release syndrome (CRS) (Phase I and II) — 1 year; Estimate rates of CMV reactivation requiring preemptive therapy. (Phase I and II) — 100 days; Estimate rates of any chronic GVHD and moderate/severe chronic GVHD at one year (Phase I and II) — 1 year
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Rapamycin · 100%Title contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.